ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.

Regina M Myers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.